Effect of long-term beta-blockade on aortic root compliance in patients with Marfan syndrome.
BACKGROUND
This study was undertaken to assess the effect of long-term beta-blockade on the aortic root stiffness index and distensibility in patients with Marfan syndrome.


METHODS
Aortic root stiffness index and distensibility were calculated according to the formulas of Stefanadis and Hirai, respectively, with 2-dimensional guided M-mode echocardiogram before and after an average of 26 months of atenolol administration.


RESULTS
Twenty-three asymptomatic patients were studied (11 men and 12 women, aged 31 +/- 14.2 years). The follow-up was 4 +/- 2.2 years. The dose of atenolol was individualized (mean 43.5 +/- 21.6 mg/d). Heart rate decreased from 79 +/- 9 beats/min to 64 +/- 9 beats/min (P =. 01), and systolic blood pressure decreased from 124 +/- 13 mm Hg to 114 +/- 2 mm Hg (P =.01). Distensibility increased from 1.85 +/- 0. 70 x 10(-6) cm2/dynes-1 to 2.21 +/- 0.76 x 10-6 cm2/dynes-1 (P =.02), and the stiffness index decreased from 9.68 +/- 3.78 to 8.85 +/- 3. 15 ( P =.2). Two groups of responses to treatment were identified. Compared with baseline values 15 (65%) patients who responded to treatment had increased distensibility and decreased stiffness index of the aortic root (P =.05). Eight patients (35%) who did not respond to treatment had no significant change. Body weight >91 kg and baseline end-diastolic aortic root diameter >40 mm were significantly associated with no response (P =.05). Two patients in the nonresponding group had echocardiographic progression of aortic insufficiency.


CONCLUSIONS
There was a heterogeneous response in the aortic root elastic properties after long-term treatment with atenolol in asymptomatic patients with Marfan syndrome. Stiffness index and distensibility are more likely to respond when the baseline end-diastolic aortic root diameter is <40 mm.
Rios
A S
AS
Cardiovascular Institute and Department of Medical Genetics, Michael Reese Hospital and Medical Center, Chicago, IL 60616, USA.
Silber
E N
EN
Bavishi
N
N
Varga
P
P
Burton
B K
BK
Clark
W A
WA
Denes
P
P
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D001011:Aorta / Q000187:drug effects* / Q000503:physiopathology; D001021:Aortic Valve / Q000187:drug effects* / Q000503:physiopathology; D001262:Atenolol / Q000494:pharmacology / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D003187:Compliance / Q000187:drug effects; D004452:Echocardiography / Q000187:drug effects; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008382:Marfan Syndrome / Q000188:drug therapy* / Q000503:physiopathology*; D008875:Middle Aged; D013997:Time Factors; D018924:Vascular Capacitance / Q000187:drug effects* / Q000502:physiology
D000319:Adrenergic beta-Antagonists; D001262:Atenolol